Published in Vaccine Weekly, September 8th, 1997
The findings by a research team from Aaron Diamond AIDS Research Center (ADARC) and Scripps Research Institute are based on intensive studies of a single human MAb, IgG1b12.
"The results suggest that escape from IgG1b12 neutralization is due to a local rather than a global modification of the gp120 [HIV envelope protein] structure," ADARC researcher Hongmei Mo et al. observed. "Our findings have implications for the therapeutic and prophylactic applications of antibodies for HIV-1 infection."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.